<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03864042</url>
  </required_header>
  <id_info>
    <org_study_id>ARRAY-818-103</org_study_id>
    <secondary_id>C4221003</secondary_id>
    <secondary_id>2019-001036-66</secondary_id>
    <nct_id>NCT03864042</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors</brief_title>
  <official_title>An Open-label Phase 1 Study to Evaluate Drug-Drug Interactions of Agents Co-Administered With Encorafenib and Binimetinib in Patients With BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pierre Fabre Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, 3-arm, fixed-sequence study to evaluate the effect of single and&#xD;
      multiple oral doses of encorafenib in combination with binimetinib on the single oral dose&#xD;
      pharmacokinetics (PK) of cytochrome P450 (CYP) enzyme probe substrates using a probe&#xD;
      cocktail, on an organic anion-transporting polypeptide/breast cancer resistance protein&#xD;
      (OATP/BCRP) substrate using rosuvastatin and on a CYP2B6 substrate using bupropion. The&#xD;
      effect of multiple oral doses of the moderate cytochrome P450 (CYP) inhibitor modafinil on&#xD;
      encorafenib in combination with binimetinib will also be assessed. The study will have 2&#xD;
      treatment phases, a drug-drug interaction (DDI) phase followed by a post-DDI phase.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 3, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Probe substrate peak plasma concentration (Cmax) in Arms 1 and 2</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Probe substrate concentration from time zero to the time of last quantifiable concentration (AUClast) in Arms 1 and 2</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in the amount of probe eliminated via urine over an 8-hour period (Ae0-8) in Arm 1</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in plasma encorafenib and LHY746 Cmax and area under the concentration time curve (AUC) in Arm 3.</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 15 and Day 21 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolite ratio (MRAUC) for 1-OH midazolam/midazolam, paraxanthine/caffeine, 5-hydroxy omeprazole/omeprazole, hydroxybupropion/bupropion and LHY746/encorafenib</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolite ratio (MRCmax) for 1-OH midazolam/midazolam, paraxanthine/caffeine, 5-hydroxy omeprazole/omeprazole, hydroxybupropion/bupropion and LHY746/encorafenib</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolite ration (MRAe0-8) for E-3174/losartan and dextrorphan/dextromethorphan</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (time to reach Cmax [Tmax]) in plasma for midazolam, 1-OH midazolam, caffeine, paraxanthine, omeprazole, 5-hydroxy omeprazole, rosuvastatin, bupropion and hydroxybupropion</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (AUC from time zero extrapolated to infinity [AUCinf]) in plasma for midazolam, 1-OH midazolam, caffeine, paraxanthine, omeprazole, 5-hydroxy omeprazole, rosuvastatin, bupropion and hydroxybupropion</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (percent of AUC extrapolated [AUC%extrap]) in plasma for midazolam, 1-OH midazolam, caffeine, paraxanthine, omeprazole, 5-hydroxy omeprazole, rosuvastatin, bupropion and hydroxybupropion</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (apparent terminal elimination half-life [T1/2]) in plasma for midazolam, 1-OH midazolam, caffeine, paraxanthine, omeprazole, 5-hydroxy omeprazole, rosuvastatin, bupropion and hydroxybupropion</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (apparent terminal elimination rate constant [Kel]) in plasma for midazolam, 1-OH midazolam, caffeine, paraxanthine, omeprazole, 5-hydroxy omeprazole, rosuvastatin, bupropion and hydroxybupropion</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (apparent total body clearance after extravascular administration [CL/F]) in plasma for midazolam, 1-OH midazolam, caffeine, paraxanthine, omeprazole, 5-hydroxy omeprazole, rosuvastatin, bupropion and hydroxybupropion</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (apparent total volume of distribution after extravascular administration [Vz/F]) in plasma for midazolam, 1-OH midazolam, caffeine, paraxanthine, omeprazole, 5-hydroxy omeprazole, rosuvastatin, bupropion and hydroxybupropion</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (urine concentration [Curine]) for losartan, E-3174, dextromethorphan and dextrorphan</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day-7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (quantity of urine excreted during each collection interval) for losartan, E-3174, dextromethorphan and dextrorphan</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (cumulative amount excreted in urine during each collection interval [CumA]e) for losartan, E-3174, dextromethorphan and dextrorphan</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (percentage of dose recovered in urine [Fe] %) for losartan, E-3174, dextromethorphan and dextrorphan</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day -7, Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Cmax) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (AUClast) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Tmax) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (AUCinf,) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 1 and Day 14 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (AUC%extrap) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 1 and Day 14 in Arms 1 and 2 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Kel) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 1 and Day 14 in Arms 1 and 2 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (T1/2) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 1 and Day 14 in Arms 1 and 2 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (CL/F) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 1 and Day 14 in Arms 1 and 2 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Vz/F) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 1 and Day 14 in Arms 1 and 2 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Cmax) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 15 and Day 21 in Arm 3 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (AUClast) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 15 and Day 21 in Arm 3 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Tmax) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 15 and Day 21 in Arm 3 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (AUCinf,) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 15 and Day 21 in Arm 3 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (AUC%extrap) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 15 and Day 21 in Arm 3 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Kel) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 15 and Day 21 in Arm 3 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (CL/F) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 15 and Day 21 in Arm 3 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (T1/2) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 15 and Day 21 in Arm 3 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Vz/F) for encorafenib, LHY746, binimetinib and AR00426032</measure>
    <time_frame>multiple timepoints over 8 hours post dose on Day 15 and Day 21 in Arm 3 (Drug-Drug Interaction (DDI) phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety will be evaluated by monitoring adverse events (AEs)</measure>
    <time_frame>From first dose of study intervention/treatment until the end of DDI phase (through 28 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>Arm 1 - CYP Probe Cocktail</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a single oral dose of the CYP Probe Cocktail on Day -7, Day 1, and Day 14:&#xD;
25 mg losartan oral tablet&#xD;
30 mg dextromethorphan oral capsule&#xD;
50 mg caffeine oral liquid&#xD;
20 mg omeprazole oral capsule&#xD;
2 mg midazolam oral syrup&#xD;
encorafenib/binimetinib continuous daily dosing starting Day 1:&#xD;
450 mg (6 x 75 mg) encorafenib oral capsules once daily (QD)&#xD;
45 mg (3 x 15 mg) binimetinib oral tablet twice daily (BID)&#xD;
All drugs will be taken within 10 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 - Rosuvastatin and Bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a single oral dose of rosuvastatin and bupropion once on Day -7, Day 1 and Day 14:&#xD;
10 mg rosuvastatin oral tablet&#xD;
75 mg bupropion immediate release (IR) oral tablet&#xD;
encorafenib/binimetinib continuous daily dosing starting Day 1:&#xD;
450 mg (6 x 75 mg) encorafenib oral capsules once daily (QD)&#xD;
45 mg (3 x 15 mg) binimetinib oral tablet twice daily (BID)&#xD;
All drugs will be taken within 10 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 - Modafinil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will begin encorafenib/binimetinib continuous daily dosing starting Day 1:&#xD;
450 mg (6 x 75 mg) encorafenib oral capsules once daily (QD)&#xD;
45 mg (3 x 15 mg) binimetinib oral tablet twice daily (BID)&#xD;
then receive continuous treatment of modafinil on Day 15 through Day 21:&#xD;
- 400 mg modafinil tablet once daily (QD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>losartan</intervention_name>
    <description>taken orally</description>
    <arm_group_label>Arm 1 - CYP Probe Cocktail</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dextromethorphan</intervention_name>
    <description>taken orally</description>
    <arm_group_label>Arm 1 - CYP Probe Cocktail</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>caffeine</intervention_name>
    <description>taken orally</description>
    <arm_group_label>Arm 1 - CYP Probe Cocktail</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omeprazole</intervention_name>
    <description>taken orally</description>
    <arm_group_label>Arm 1 - CYP Probe Cocktail</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>midazolam</intervention_name>
    <description>taken orally</description>
    <arm_group_label>Arm 1 - CYP Probe Cocktail</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosuvastatin</intervention_name>
    <description>taken orally</description>
    <arm_group_label>Arm 2 - Rosuvastatin and Bupropion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupropion immediate release (IR)</intervention_name>
    <description>taken orally</description>
    <arm_group_label>Arm 2 - Rosuvastatin and Bupropion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>encorafenib</intervention_name>
    <description>taken orally</description>
    <arm_group_label>Arm 1 - CYP Probe Cocktail</arm_group_label>
    <arm_group_label>Arm 2 - Rosuvastatin and Bupropion</arm_group_label>
    <arm_group_label>Arm 3 - Modafinil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>binimetinib</intervention_name>
    <description>taken orally</description>
    <arm_group_label>Arm 1 - CYP Probe Cocktail</arm_group_label>
    <arm_group_label>Arm 2 - Rosuvastatin and Bupropion</arm_group_label>
    <arm_group_label>Arm 3 - Modafinil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>modafinil</intervention_name>
    <description>taken orally</description>
    <arm_group_label>Arm 3 - Modafinil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria - Patients must meet all of the inclusion criteria to be eligible&#xD;
        for enrollment into the study:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of locally advanced, unresectable or metastatic&#xD;
             cutaneous melanoma or unknown primary melanoma American Joint Committee on Cancer&#xD;
             (AJCC) Stage IIIB, IIIC or IV; or other BRAF V600-mutant advanced solid tumors&#xD;
&#xD;
          -  Presence of BRAF V600E and/or V600K mutation in tumor tissue prior to enrollment, as&#xD;
             determined using a local test;&#xD;
&#xD;
          -  Evidence of measurable or non-measurable lesions&#xD;
&#xD;
          -  Patient with unresectable locally advanced or metastatic melanoma who has received no&#xD;
             prior treatment or progressed on or after prior systemic therapy; Note: Prior therapy&#xD;
             with a BRAF proto-oncogene serine-threonine protein kinase (BRAF) inhibitor and/or a&#xD;
             mitogen-activated protein (MAP) kinase (MEK) inhibitor is permitted except in the&#xD;
             regimen immediately prior to study entry&#xD;
&#xD;
          -  Patient with other (non-melanoma) BRAF V600E and/or V600K -mutant advanced solid&#xD;
             tumors who has progressed on standard therapy or for whom there are no available&#xD;
             standard therapies; Note: Prior therapy with a BRAF inhibitor and/or a MEK inhibitor&#xD;
             is permitted except in the regimen immediately prior to study entry&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1&#xD;
&#xD;
          -  Adequate bone marrow, hepatic and renal function as specified in the protocol&#xD;
&#xD;
          -  ARM 1 ONLY: Non-smoker who has not used nicotine containing products for at least 3&#xD;
             months prior to the first dose.&#xD;
&#xD;
        Key Exclusion Criteria - Patients meeting any of the following criteria are not eligible&#xD;
        for enrollment in the study:&#xD;
&#xD;
          -  Symptomatic brain metastasis. Patients previously treated or untreated for these&#xD;
             conditions that are asymptomatic in the absence of corticosteroid and anti-epileptic&#xD;
             therapy are allowed. Brain metastases must be stable, with imaging (e.g., magnetic&#xD;
             resonance imaging [MRI] or computed tomography [CT] demonstrating no current evidence&#xD;
             of progressive brain metastases at screening);&#xD;
&#xD;
          -  Symptomatic or untreated leptomeningeal disease;&#xD;
&#xD;
          -  History or current evidence of retinal vein occlusion (RVO) or current risk factors&#xD;
             for RVO (e.g., uncontrolled glaucoma or ocular hypertension, history of hyperviscosity&#xD;
             or hypercoagulability syndromes);&#xD;
&#xD;
          -  Clinically significant cardiac disease&#xD;
&#xD;
          -  Known hyper-coagulability risks other than malignancy (e.g., Factor V Leiden&#xD;
             syndrome);&#xD;
&#xD;
          -  Thromboembolic event except catheter-related venous thrombosis ≤ 12 weeks prior to&#xD;
             starting study treatment.&#xD;
&#xD;
          -  Discontinuation of prior BRAF and/or MEK inhibitor treatment due to left ventricular&#xD;
             dysfunction, pneumonitis/interstitial lung disease, or retinal vein occlusion;&#xD;
&#xD;
          -  ARM 1 ONLY: Positive urine cotinine test at screening&#xD;
&#xD;
          -  ARM 3 ONLY:&#xD;
&#xD;
               -  History of psychosis, depression or mania;&#xD;
&#xD;
               -  History of angioedema;&#xD;
&#xD;
               -  History of mitral valve prolapse;&#xD;
&#xD;
               -  History of left ventricular hypertrophy;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Irvine Health</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868-3201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital - Anschutz Cancer Pavilion (ACP)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regions Cancer Care Center</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HealthPartners Specialty Center-Eye Care</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of TN Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Centers - Medical City Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Utah Cancer Specialists</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen Pharmacy</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Maarten</name>
      <address>
        <city>Mechelen</city>
        <state>Antwerpen</state>
        <zip>02800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Maarten</name>
      <address>
        <city>Mechelen</city>
        <zip>02800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montrea</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Beata Maria Ana</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Rementeria</name>
      <address>
        <city>Madrid</city>
        <zip>28010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro - CIOCC</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CERCO</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=ARRAY-818-103</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 1, 2019</study_first_submitted>
  <study_first_submitted_qc>March 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2019</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>solid tumor</keyword>
  <keyword>melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Dextromethorphan</mesh_term>
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Modafinil</mesh_term>
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

